Spine Align Raises $1.75M Series Seed Round

September 14, 2020

Spine Align, LLC, a medical device company developing a portfolio of products that enable spine surgeons to measure, visualize, and adjust patients’ spinal alignment during surgery, recently closed a $1.75M Series Seed round.

Spine Align reports the financing is led by the Rockies Venture Club, with additional support by members of the Berkeley Angel Network, NO/LA Angel Network, Pasadena Angels, Bellingham Angels, the Abell Foundation, and VentureWell. This round supports development efforts to achieve FDA 510(k) clearance for their flagship product, LiveAlignTM, in 2021.

“This milestone is a culmination of years of tireless work by our team to build an innovative platform of products that rethink what’s possible for spine surgeons today. We could not be more grateful to our investor partners, medical and business advisory board members, and engineering team to bring us to where we are today and where we are heading,” said Amir Soltanianzadeh, CEO & Co-Founder.

“The solution that Spine Align has developed will have a dramatic impact on spinal surgery. Rockies Venture Club was proud to lead this funding round and found that many investors across the country saw the same potential in the company,” added Dave Harris, Director of Operations at Rockies Venture Club.

“This funding round represents a tremendous milestone of being closer to positively impacting the lives of patients with our technology. LiveAlignTM is just the first of many products in our portfolio that will seamlessly augment the art of surgery with digital feedback,” said Dr. David Gullotti, CTO & Co-Founder.

“The Spine Align platform leverages the infrastructure of image-guided and robotic technologies to deliver the next generation of surgery. My colleagues and I cannot wait to use this breakthrough technology in the operating room next year,” said Dr. Nicholas Theodore, Co-Founder of Spine Align and Director of the Neurological Spine Program at the Johns Hopkins Hospital.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version